Vivek Ramaswamys Former Company Is Doing Just Fine Without Him Mint - Mint
| PAR Stock | 121.89 2.35 1.89% |
About 62% of Par Drugs' investor base is looking to short. The analysis of overall sentiment of trading Par Drugs And stock suggests that many investors are alarmed at this time. The current market sentiment, together with Par Drugs' historical and current headlines, can help investors time the market. In addition, many technical investors use Par Drugs And stock news signals to limit their universe of possible portfolio assets.
Par Drugs stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Par daily returns and investor perception about the current price of Par Drugs And as well as its diversification or hedging effects on your existing portfolios.
Par |
Vivek Ramaswamys Former Company Is Doing Just Fine Without Him Mint Mint
Read at news.google.com
 |
Par Drugs Fundamental Analysis
We analyze Par Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Par Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Par Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Par Drugs is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Par Drugs And Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Par Drugs stock to make a market-neutral strategy. Peer analysis of Par Drugs could also be used in its relative valuation, which is a method of valuing Par Drugs by comparing valuation metrics with similar companies.
Peers
Par Drugs Related Equities
| SPTL | Sintex Plastics | 0.00 |
| ||
| FEDFINA | Fedbank Financial | 0.12 |
| ||
| ABDL | Allied Blenders | 0.51 |
| ||
| MANINFRA | Man Infraconstructio | 1.07 |
| ||
| KNRCON | KNR Constructions | 1.67 |
| ||
| GMBREW | GM Breweries | 2.73 |
| ||
| KEYFINSERV | Keynote Financial | 4.69 |
|
Complementary Tools for Par Stock analysis
When running Par Drugs' price analysis, check to measure Par Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Par Drugs is operating at the current time. Most of Par Drugs' value examination focuses on studying past and present price action to predict the probability of Par Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Par Drugs' price. Additionally, you may evaluate how the addition of Par Drugs to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |